Overall verdict
Buy
6.7/10
1-year performance
+45.02%
Score breakdown
Up 45.0% over 1 year, 52% of the 52-week range.
Strongest: Valuation 8.8/10. Weakest: Financial strength 1.4/10.
8 analysts, target +0.3% vs the price.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nyse
United States
CEO
Javier Rodriguez
Founded
1994
Employees
78 000
Revenue / employee
174 911 USD
Next earnings
February 11, 2027 (estimated)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC2.00%
- Bank of New York Mellon Corp0.37%
- FMR LLC0.07%
- Rest of the register97.57%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
247.49 USD
52-week low
101.00 USD
1-year performance
45.02%
Rising
Year-to-date performance
55.63%
Rising
Drawdown
-28.52%
Marked drawdown
Position in the 52-week range
52% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned much more, but shaking 2.0 times harder: once that risk is counted, it did about as well as the ETF.
$10,000 placed at the end of December 2000 are worth today
| DaVita | $328,467 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 2.0 times as much as the world ETF.
- Worst fall:-51Â % between August 2021 and November 2022. $10,000 placed at the top fell to $4,890. The world ETF, at worst: -53Â %. Back to its high in 16 months.
DaVita earned 5 times as much as the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- DaVita: $328,467
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Share price without dividends; the world ETF and the index reinvest theirs. A dividend payer is therefore understated here.
Based on past performance. This is not a recommendation.
Range: 311.75 USD - 431.11 USD (2 methods agree)
The price implies growth of -6.23% per year; the company grows at 8.29%.
Gross margin 27.4%, net margin 6.3%, ROIC 7.5%, ROE -158.2%.
Net margin
6.32%
Exceptional
Sector 4.51%|S&P 13.40%
Gross margin
27.35%
Fair
Return on equity (ROE)
-158.23%
Negative
Sector 10.43%|S&P 17.06%
Return on invested capital (ROIC)
7.47%
High
Free cash flow margin (FCF)
9.13%
High
Profit-to-cash conversion (FCF conversion)
1.45x
High
Margin stability
1.9 pts
Very steady
Revenue to net income
Growth
7.7/10Revenue up 4.6% over 1 year, 3.4% a year over 5, EPS 8.3% a year over 5.
Revenue (trailing 12 months)
14.2Md USD
Revenue growth (1y)
4.62%
Moderate
Revenue growth (3y)
17.51%
Solid
EPS growth (1y)
67.00%
Hyper-growth
EPS CAGR (5y)
8.29%
Fair
EPS revisions (3 months)
-1.00%
Revised down
Valuation
8.8/10P/E 13.4x, forward P/E 12.3x, EV/EBITDA 7.5x, PEG 1.61. The multiple sits in the 87th percentile of its own 5-year history.
P/E (TTM)
13.4x
Cheap
Sector 27.8x|S&P 23.6x
Forward P/E
12.3x
Cheap
EV / EBITDA
7.5x
Cheap
Sector 12.6x|S&P 15.5x
PEG
1.61
Expensive
Sector 0.67|S&P 0.91
Fair value (reverse DCF)
371.31 USD
Deeply undervalued
P/E vs its own 5-year history
among the 13% highest valuations
At its historical high
Market cap
11.1Md USD
Financial strength
1.4/10Cash covers 4.9% of the debt, net debt/EBITDA 4.5x.
Net debt / EBITDA
4.5x
Stretched
Gearing (net debt / equity)
1131.84%
Stretched
Cash
650M USD
Cash / market cap
5.84%
Tight
Cash / total debt
4.85%
Stretched
Interest coverage
3.8x
Tight
Net debt
12.7Md USD
Equity
1.1Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 179.28 USD
- MM20185.40
- MM50182.76
- MM200179.84
- RSI 1444.8
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+4.59%
200-day average slope, 3 months
+12.86%
50-day average slope, 1 month
+0.24%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
3.11 % per day
Volatility change
+20.10%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 14.33 (3) | 14.77 (7) | 14 248 (6) | 2 905 (7) | 937 (3) |
| 2027 | 17.10 (3) | 16.88 (8) | 14 751 (7) | 2 979 (7) | 1 014 (3) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 11, 2026.
Same sub-industry: 76 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DVA | 6.7 | 6.7 | 11.1Md USD | 13.4x | 6.3 % | 4.6 % | 7.5 % | 4.5x | 11.6 % | 45.0 % | ||
| 2 | CVS | 6.5 | 6.0 | 115Md USD | 10.4x | 2.6 % | 5.4 % | 7.4 % | 4.1x | 13.6 % | 14.8 % | ||
| 3 | HNGE | 6.4 | 7.0 | 9.5Md USD | 61.3x | 20.7 % | 52.4 % | 44.7 % | -1.6x | 3.3 % | 171.5 % | ||
| 4 | DGX | 6.1 | 6.1 | 28.5Md USD | 25.8x | 9.5 % | 10.0 % | 8.4 % | 2.8x | 4.8 % | 39.8 % | ||
| 5 | CI | 6.1 | 6.1 | 79.4Md USD | 13.3x | 2.1 % | 5.7 % | 8.3 % | 1.8x | 10.4 % | 15.8 % | ||
| 6 | BTSG | 6.0 | 4.7 | 14.5Md USD | 47.2x | 2.0 % | 26.4 % | 7.0 % | 4.6x | 3.4 % | 116.3 % | ||
| 7 | FME | 5.4 | 5.4 | 12.0Md USD | 13.6x | 4.2 % | 1.1 % | 3.8 % | 2.7x | 17.0 % | -0.5 % | ||
| 8 | GH | 5.3 | 3.6 | 20.9Md USD | Not meaningful (loss) | -37.9 % | 36.1 % | -41.6 % | -1.4x | -1.1 % | 59.9 % | ||
| 9 | LH | 5.3 | 4.4 | 30.2Md USD | 30.5x | 6.9 % | 6.9 % | 6.8 % | 2.4x | 4.3 % | 41.7 % |
